Login / Signup

Selection Route of Precursor Materials in 3D Printing Composite Filament Development for Biomedical Applications.

Aura-Cătălina MocanuFlorin MiculescuAndreea-Elena ConstantinescuMădălina-Andreea PandeleStefan Ioan VoicuAnișoara CîmpeanMarian MiculescuAndreea Mariana Negrescu
Published in: Materials (Basel, Switzerland) (2023)
Additive manufacturing or 3D printing technologies might advance the fabrication sector of personalised biomaterials with high-tech precision. The selection of optimal precursor materials is considered the first key-step for the development of new printable filaments destined for the fabrication of products with diverse orthopaedic/dental applications. The selection route of precursor materials proposed in this study targeted two categories of materials: prime materials, for the polymeric matrix (acrylonitrile butadiene styrene (ABS), polylactic acid (PLA)); and reinforcement materials (natural hydroxyapatite (HA) and graphene nanoplatelets (GNP) of different dimensions). HA was isolated from bovine bones (HA particles size < 40 μm, <100 μm, and >125 μm) through a reproducible synthesis technology. The structural (FTIR-ATR, Raman spectroscopy), morphological (SEM), and, most importantly, in vitro (indirect and direct contact studies) features of all precursor materials were comparatively evaluated. The polymeric materials were also prepared in the form of thin plates, for an advanced cell viability assessment (direct contact studies). The overall results confirmed once again the reproducibility of the HA synthesis method. Moreover, the biological cytotoxicity assays established the safe selection of PLA as a future polymeric matrix, with GNP of grade M as a reinforcement and HA as a bioceramic. Therefore, the obtained results pinpointed these materials as optimal for future composite filament synthesis and the 3D printing of implantable structures.
Keyphrases
  • drug delivery
  • cancer therapy
  • raman spectroscopy
  • tissue engineering
  • mass spectrometry
  • dna damage
  • drug release
  • current status
  • walled carbon nanotubes